Family Care (516110)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 7/9 suggests recent improvement in financial health.
• Reported ROCE of 79.25% indicates high return on capital employed, if the numbers are reliable.
• Stock has moved from ₹2.55 to ₹7.44 over 52 weeks, showing market interest.
• Book value per share of ₹2.97 provides some asset backing, though price is above it.

Concerns

• Latest quarter has zero sales (₹0 Cr) and a net loss of ₹1 Cr, so there is no operating revenue to value.
• ROE of -36.49% means shareholder equity is being eroded while the stock trades at 2.51 times book value.
• P/E is meaningless due to losses, and the ₹7.44 price offers no earnings support.
• Promoter holding and debt/equity are N/A, making transparency insufficient for a microcap investor.

AI Analysis

Imagine sitting across from a business that has no sales. That is Family Care today. The latest quarter shows ₹0 crore of revenue and a net loss of ₹1 crore, so the 0.00 P/E is not a bargain signal—it is a warning. As Graham taught, price is what you pay; value is what you get. Here the price is ₹7.44, while book value is only ₹2.97. I am being asked to pay 2.5 times book for a company earning -36.49% on equity. That fails every value test I apply. The Piotroski F-Score of 7/9 is the one bright number. It hints that balance-sheet stress may be easing. But a high F-Score without revenue is like a healthy pulse on a patient who cannot breathe. ROCE of 79.25% looks impressive, yet with zero sales I cannot trust it as a measure of an operating franchise. Debt/equity is N/A, promoter holding is N/A—for a microcap at ₹40 crore, missing data should make an investor more cautious, not less. Sales growth and profit growth are both 0.00%, which means there is no demonstrated growth engine. There is no dividend for the patient holder. The share has risen from ₹2.55 to ₹7.44 over 52 weeks, but a rising stock is not a moat. Without earnings, without revenue, and without clarity on capital structure, this is not a compounder. It is a speculative turnaround candidate. I would not buy here. I want to see at least a few quarters of real sales, positive operating profit, and evidence that the F-Score improvements are translating into cash earnings. Only then might the book value become meaningful. Until then, the margin of safety is absent, and the arithmetic does not work.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer